Posted on

Developing psychedelic treatments for ADHD and social anxiety

Filament Health and Jaguar Health Sign Letter of Intent to Develop Botanical Prescription Drugs for Specific Mental Health Indications

Filament Health (FH) announced several exciting updates this week.

First, the company shared that it has successfully developed a pharmaceutical-grade ayahuasca extract that can be administered in a capsule.

Filament also announced that it cultivated its 70th variety of psilocybin mushrooms and is conducting research to determine the most potent and effective variety.

Additionally, the Vancouver-based company is partnering with Jaguar Health to develop natural psychedelic medicines for neurodegenerative diseases, addiction, and mental health disorders. The partners are currently identifying plant candidates to treat ADHD and social anxiety disorder.

PDF of article 1

PDF of article 2

Posted on

How psychedelics change your social life

How Do Psychedelics Change Your Personality? These Researchers Tried To Find Out

Researchers developed a personality model to test how psychedelics affect the qualities that help us build and maintain healthy relationships.

They discovered that after taking psychedelics, participants felt:

  • Less critical in their interactions with others,
  • Less anxious,
  • Less likely to get upset easily,
  • Greater feelings of social connectedness

How do you see psychedelics changing your relationships?

PDF of article

Posted on

Cybin targets general and social anxiety with new proprietary pyschedelic molecule

Cybin Selects Anxiety Disorder Indications for Proprietary Psychedelic Molecule CYB004

Cybin Inc. (CYBN) announced that their new psychedelic molecule called CYB004 will target social anxiety disorder (SAD) and general anxiety disorder (GAD). Cybin’s Chief Clinical Officer says that anxiety disorders have increased three-fold during the COVID-19 pandemic, increasing the global market size to an estimated US$1.15B for SAD and US$2.99B for GAD. Cybin hopes to tap into this market, as many patients do not respond well to current anxiety medications such as SSRIs and SNRIs.

PDF of article